The angiopoietin/tie-2 axis: A novel player in chronic kidney disease

Minerva Urologica e Nefrologica

Volumn 62, Issue 3, 2010, Pages 319-326

  David, S ^a,b   Haller, H ^a   Kumpers P ^a,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Angiopoietins; Atherosclerosis; Dialysis; Inflammation; Kidney failure, chronic

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; OLMESARTAN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; ATHEROSCLEROSIS; CELL ACTIVATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HEALTH STATUS; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PERICYTE; PROTEIN PHOSPHORYLATION; RENAL REPLACEMENT THERAPY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; INFLAMMATION; KIDNEY DISEASES; RECEPTOR, TIE-2; RENAL DIALYSIS;

EID: 78751681509     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
2. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003;41:11-7.
3. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007;18:293-303.
4. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005;46:186-202.
5. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008;3:61-8.
6. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-7.
7. Roberts MA, Hare DL, Ratnaike S, Ierino FL. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 2006;48:341-60.
8. Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 2006;98:1014-23.
9. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006;27:552-8.
10. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ Res 2000;86:24-9.
11. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70-4.
12. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
13. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
14. Hughes DP, Marron MB, Brindle NP: The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2. Circ Res 2003;92:630-6.
15. Tadros A, Hughes DP, Dunmore BJ, Brindle NP. ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1. Blood 2003;102:4407-09.
16. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103:4150-6.
17. Mandriota SJ, Pyke C, Di Sanza C, Quinodoz P, Pittet B, Pepper MS: Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. Am J Pathol 2000;156:2077-89.
18. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999;274:15732-9.
19. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66.
20. Lukasz A, Hellpap J, Horn R, Kielstein JT, David S, Haller H et al. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Crit Care 2008;12:R94.
21. Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005;180:113-8.
22. Nykänen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Ylä-Herttuala S et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003;107:1308-14.
23. Nadar SK, Blann A, Beevers DG, Lip GY. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 2005;258:336-43.
24. Patel JV, Lim HS, Varughese GI, Hughes EA, Lip GY Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med 2008;40:215-22.
25. Kümpers P, Hellpap J, David S, Horn R, Leitolf H, Haller H et al. Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. Nephrol Dial Transplant 2009;24:1845-50.
26. David S, Kümpers P, Hellpap J, Horn R, Leitolf H, Haller H et al. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis 2009;53:770-8.
27. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004;110:2355-60.
28. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006;12:235-9.
29. Post S, Peeters W, Busser E, Lamers D, Sluijter JP, Goumans MJ et al. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 2008;45:244-50.
30. McCarter SD, Lai PF, Suen RS, Stewart DJ. Regulation of endothelin-1 by angiopoietin-1: implications for inflammation. Exp Biol Med (Maywood) 2006;231:985-91.
31. Ahmed A, Fujisawa T, Niu XL, Ahmad S, Al-Ani B, Chudasama K et al. Angiopoietin-2 confers Atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide. Circ Res 2009;104: 1333-6.
32. Lim HS, Blann AD, Chong AY, Freestone B, Lip GY Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004;27:2918-24.
33. David S, Kumpers P, Lukasz A, Kielstein JT, Haller H, Fliser D. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/ pravastatin. J Hypertens 2009;27:1641-7.
34. akuchi M, Greer JJ, Cameron SJ, Matsushita K, Morrell CN, Talbot-Fox K et al. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res 2005;96:1185-92.
35. Vanholder R, Glorieux G, Lameire N. Uraemic toxins and cardiovascular disease. Nephrol Dial Transplant 2003;18:463-6.
36. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27:3557-65.